DigestRedComo funciona
Red
/
Empresas
Ka
No verificado

Kallyope

Sobre qué escribimos

BiotecnologíaEventosFarmacéuticaMedicina - VariosSalud

7 Comunicados de prensa

Ver todos los comunicados de prensa
22/04/2026
Kallyope’s Phase 2b Study of Elismetrep, A Novel Approach for Treating Migraine, Presented at the American Academy of Neurology Annual Meeting
Fuente
Kallyope
Editor
Business Wire
1.00
0
05/03/2026
Eventos
Ciencia
Técnica
Tecnología
Medicina - Varios
Biotecnología
Farmacéutica
Salud
Kallyope to Present Phase 2b Study Results for Elismetrep for the Acute Treatment of Migraine at the 2026 American Academy of Neurology Annual Meeting
Fuente
Kallyope
Editor
Business Wire
1.00
0
07/01/2026
Biotecnología
Sanidad
Salud
Farmacéutica
Medicina - Varios
Kallyope Announces 2026 Strategic Priorities for Migraine and Metabolism Portfolio Based on Novel Neural Circuits Platform
Fuente
Kallyope
Editor
Business Wire
1.00
0
18/12/2025
Eventos
Biotecnología
Sanidad
Salud
Farmacéutica
Kallyope To Present at the 44th Annual J.P. Morgan Healthcare Conference
Fuente
Kallyope
Editor
Business Wire
1.00
0
17/12/2025
Eventos
Biotecnología
Sanidad
Salud
Farmacéutica
Kallyope To Present at the 44th Annual J.P. Morgan Healthcare Conference
Fuente
Kallyope
Editor
Business Wire
1.00
0
08/12/2025
Industria
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of Migraine
Fuente
Kallyope
Editor
Business Wire
1.00
0
10/09/2024
Mercado laboral
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Kallyope Announces License Agreement with Novo Nordisk
Fuente
Kallyope
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0